The Evidence Behind Genomically Guided Cancer Therapy
Australia’s Molecular Screening and Therapeutic (MoST) program has delivered the most rigorous national evidence to date that precision oncology works—conditionally. Published in JAMA Oncology in May 2026, the landmark cohort study analysed 3,383 patients with advanced, refractory cancers who underwent comprehensive genomic profiling. Researchers found that 37.5% of patients harboured clinically active biomarkers classified as tiers 1–3A under the TOPOGRAPH evidence framework.
The survival data were striking. Patients receiving therapies matched to these high-confidence biomarkers achieved a median overall survival of 21.2 months, compared with 12.8 months for those receiving unmatched therapy—a 40% reduction in mortality risk. However, the study delivered an equally important caveat: therapies matched using only preclinical evidence or repurposed from other cancer types showed no survival benefit whatsoever. The message is unambiguous: genomic matching works when evidence is strong, and fails when it is not.
Omico’s PrOSPeCT 2.0: Scaling Access Beyond Clinical Trials
Omico, Australia’s national precision oncology platform, has become the operational backbone for translating MoST’s findings into clinical reality. In June 2026, Omico announced the expansion of its real-world data initiative, built on Australia’s largest prospectively consented precision oncology dataset—now exceeding 20,000 records. This dataset integrates genomic, clinical, and outcomes data, offering industry and research partners unprecedented visibility into biomarker-defined patient populations and treatment trajectories.
The program’s continuity is secured through the federal government’s $71 million investment over three years, enabling PrOSPeCT 2.0 to provide free comprehensive genomic profiling and treatment matching for Australians with advanced, incurable cancers. Crucially, this includes patients in rural and remote areas who historically faced significant access barriers to genomic testing.
The Biomarker Testing Explosion
Medicare data reveal the scale of Australia’s precision oncology evolution. Between 2010 and 2024, annual cancer biomarker test claims increased nearly fivefold, from 5,130 to 25,374. Median reimbursement per test rose from AU$339 in 2014 to AU$667 in 2024, reflecting a shift toward multigene panel testing that captures actionable variants across multiple therapeutic targets simultaneously.
Yet comprehensive genomic profiling—including large panels, whole exome sequencing, and whole genome sequencing—remains not routinely funded across solid tumours in standard clinical care. The gap between research-grade genomic capability and funded clinical access persists as the central policy challenge for 2026 and beyond.
Real-World Data as a Sustainability Engine
Omico’s real-world data offering represents a novel funding model for precision oncology. Revenue generated through industry collaborations is reinvested into the not-for-profit mission, supporting continued patient access while building a more sustainable national model. As CEO Ian Black framed it: “Our responsibility is to ensure that every investment Omico receives delivers meaningful outcomes for patients”.
Professor David Thomas, Omico’s Founder and Chief Science and Strategy Officer, emphasised that as cancer care becomes increasingly biomarker-driven, generating meaningful evidence in smaller patient populations becomes both more challenging and more essential. Australia’s precision oncology framework in 2026 is not merely about matching drugs to mutations—it is about building the evidence infrastructure, data systems, and funding models that make genomic cancer care scalable, equitable, and durable.
